ATRA Insider Trading
Insider Ownership Percentage: 3.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $218,489.87
Atara Biotherapeutics Insider Trading History Chart
This chart shows the insider buying and selling history at Atara Biotherapeutics by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Atara Biotherapeutics Share Price & Price History
Current Price: $5.53
Price Change: ▲ Price Increase of +0.23 (4.34%)
As of 04/11/2025 05:00 PM ET
Atara Biotherapeutics Insider Trading History
Atara Biotherapeutics Institutional Trading History
Data available starting January 2016
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Read More on Atara Biotherapeutics
Volume
57,867 shs
Average Volume
123,252 shs
Market Capitalization
$32.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.32
Who are the company insiders with the largest holdings of Atara Biotherapeutics?